2 recruiting, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Higher Risk Myelodysplastic Syndromes: new trials by email Literature Review of Higher Risk Myelodysplastic Syndromes trials Research Report on Higher Risk Myelodysplastic Syndromes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes bexmarilimab (1mg/kg), azacitidine, Placebo - Higher Risk Myelodysplastic Syndromes | Phase 2 | Recruiting | Faron Pharmaceuticals Ltd | 90 | 2026-10-01 | 2026-10-20 |
| Study of REM-422 in Patients With AML or Higher Risk MDS REM-422 - Myelodysplastic Syndromes, Higher Risk Myelodysplastic Syndromes | Phase 1 | Recruiting | Remix Therapeutics | 100 | 2024-04-26 | 2026-10-29 |
| A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02) evorpacept, azacitidine - Higher Risk Myelodysplastic Syndromes | Phase 1 | Terminated | ALX Oncology Inc. | 65 | 2020-10-02 | 2025-07-20 |
Leukemia, Myeloid, Acute (1) · Myelodysplastic Syndromes (1) · Neoplasms (1)
Bone Marrow Diseases (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Leukemia (1) · Leukemia, Myeloid (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
Azacitidine (2) · ALX148 (1) · bexmarilimab (1)
ALX Oncology Inc. (1) · Faron Pharmaceuticals Ltd (1) · Remix Therapeutics (1)
United States (3) · France (2) · Czechia (1) · Finland (1) · Italy (1) · Poland (1) · South Korea (1) · Spain (1) · United Kingdom (1)